GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400(10369):2221–48.

World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper–February 2019. Wkly Epidemiol Rec. 2019;94(08):85–103.

Google Scholar 

Whitney CG, Goldblatt D, O’Brien KL. Dosing schedules for pneumococcal conjugate vaccine: considerations for policy makers. Pediatr Infect Dis J. 2014;33:S172–81.

PubMed  Google Scholar 

Schley K, Borchert K, Seidel K, Jacob C, von Eiff C, Laurenz M. Did the change of the vaccination schedule effect pneumococcal conjugate vaccination compliance and adherence of premature and mature born infants in Germany? Answers from a claims database analysis. Vaccine. 2023;41(28):4081–91.

CAS  PubMed  Google Scholar 

Grant LR, Slack MPE, Theilacker C, Vojicic J, Dion S, Reinert R-R, et al. Distribution of serotypes causing invasive pneumococcal disease in children from high-income countries and the impact of pediatric pneumococcal vaccination. Clin Infect Dis. 2023;76(3):e1062–70.

PubMed  Google Scholar 

World Health Organization. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines, Annex 3, TRS No 977. 2013.

Feemster K, Buchwald UK, Banniettis N, Joyce JG, Velentgas P, Chapman TJ, et al. Immunogenicity of current and next-generation pneumococcal conjugate vaccines in children: current challenges and upcoming opportunities. Open Forum Infect Dis. 2024;11(5): ofae220.

PubMed  PubMed Central  Google Scholar 

Korbal P, Wysocki J, Jackowska T, Kline M, Tamimi N, Drozd J, et al. Phase 3 safety and immunogenicity study of a three-dose series of twenty-valent pneumococcal conjugate vaccine in healthy infants and toddlers. Pediatr Infect Dis J. 2024;43(6):587–95.

PubMed  PubMed Central  Google Scholar 

Andrews N, Waight PA, Borrow R, Ladhani S, George RC, Slack MPE, et al. Using the indirect cohort design to estimate the effectiveness of the seven-valent pneumococcal conjugate vaccine in England and Wales. PLoS ONE. 2011;6(12): e28435.

CAS  PubMed  PubMed Central  Google Scholar 

Andrews N, Kent A, Amin-Chowdhury Z, Sheppard C, Fry N, Ramsay M, et al. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: the indirect cohort design, 2006–2018. Vaccine. 2019;37(32):4491–8.

PubMed  Google Scholar 

Andrejko KL, Gierke R, Rowlands JV, Rosen JB, Thomas A, Landis ZQ, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: an indirect cohort study. Vaccine. 2024;42(16):3555–63.

CAS  PubMed  PubMed Central  Google Scholar 

Savulescu C, Krizova P, Valentiner-Branth P, Ladhani S, Rinta-Kokko H, Levy C, et al. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study. Vaccine. 2022;40(29):3963–74.

CAS  PubMed  Google Scholar 

Amir-Behghadami M, Janati A. Population, intervention, comparison, outcomes and study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. Emerg Med J. 2020;37(6):387.

PubMed  Google Scholar 

Berman-Rosa M, O’Donnell S, Barker M, Quach C. Efficacy and effectiveness of the PCV-10 and PCV-13 vaccines against invasive pneumococcal disease. Pediatrics. 2020;145(4): e20190377.

PubMed  Google Scholar 

Conklin L, Loo JD, Kirk J, Fleming-Dutra KE, Deloria Knoll M, Park DE, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. Pediatr Infect Dis J. 2014;33:S109–18.

PubMed  Google Scholar 

McGirr A, Iqbal SM, Izurieta P, Talarico C, Luijken J, Redig J, et al. A systematic literature review and network meta-analysis feasibility study to assess the comparative efficacy and comparative effectiveness of pneumococcal conjugate vaccines. Hum Vacc Immunother. 2019;15(11):2713–24.

Google Scholar 

Wells G SB, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2024. https://www.R-project.org/.

Viechtbauer W. Conducting meta-analyses in R with the metafor Package. J Stat Softw. 2010;36(3):1–48.

Google Scholar 

Olarte L, Lin PL, Barson WJ, Romero JR, Tan TQ, Givner LB, et al. Invasive pneumococcal infections in children following transplantation in the pneumococcal conjugate vaccine era. Transpl Infect Dis. 2017;19(1): e12630.

Google Scholar 

Cohen C, von Mollendorf C, de Gouveia L, Naidoo N, Meiring S, Quan V, et al. Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in HIV-infected and -uninfected children in South Africa: a matched case–control study. Clin Infect Dis. 2014;59(6):808–18.

PubMed  PubMed Central  Google Scholar 

Cohen C, von Mollendorf C, de Gouveia L, Lengana S, Meiring S, Quan V, et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case–control study. Lancet Glob Health. 2017;5(3):e359–69.

PubMed  Google Scholar 

Gidding HF, McCallum L, Fathima P, Moore HC, Snelling TL, Blyth CC, et al. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia. Vaccine. 2018;36(19):2650–6.

CAS  PubMed  Google Scholar 

Deceuninck G, De Serres G, Boulianne N, Lefebvre B, De Wals P. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine. 2015;33(23):2684–9.

CAS  PubMed  Google Scholar 

Kabir A, Newall AT, Randall D, Moore HC, Jayasinghe S, Fathima P, et al. Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in medically at-risk children in Australia: a record linkage study. J Pediatr Infect Dis Soc. 2022;11(9):391–9.

CAS  Google Scholar 

Jayasinghe S, Chiu C, Quinn H, Menzies R, Gilmour R, McIntyre P. Effectiveness of 7- and 13-valent pneumococcal conjugate vaccines in a schedule without a booster dose: a 10-year observational study. Clin Infect Dis. 2018;67(3):367–74.

CAS  PubMed  Google Scholar 

Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case–control study. Lancet. 2006;368(9546):1495–502.

CAS  PubMed  Google Scholar 

Deceuninck G, De Wals P, Boulianne N, De Serres G. Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada. Pediatr Infect Dis J. 2010;29(6):546–9.

PubMed  Google Scholar 

Baqui AH, Koffi AK, McCollum ED, Roy AD, Chowdhury NH, Rafiqullah I, et al. Impact of national introduction of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in Bangladesh: case–control and time-trend studies. Vaccine. 2021;39(40):5794–801.

PubMed  Google Scholar 

Domingues CMAS, Verani JR, Montenegro Renoiner EI, de Cunto Brandileone MC, Flannery B, de Oliveira LH, et al. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case–control study. Lancet Respir Med. 2014;2(6):464–71.

CAS  PubMed  PubMed Central  Google Scholar 

Riaz A, Mohiuddin S, Husain S, Yousafzai MT, Sajid M, Kabir F, et al. Effectiveness of 10-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in Pakistan. Int J Infect Dis. 2019;80:28–33.

CAS  PubMed  Google Scholar 

Malaker R, Hasanuzzaman M, Hooda Y, Rahman H, Chandra Das R, Kanon N, et al. Effectiveness of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children <2 years old: a prospective population-based study in rural Bangladesh. Vaccine. 2024;42(2):255–62.

CAS  PubMed  Google Scholar 

Deceuninck G, Brousseau N, Lefebvre B, Quach C, Tapiero B, Bui Y-G, et al. Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent serotype 3 invasive pneumococcal disease in Quebec in children, Canada. Vaccine. 2023;41(38):5486–9.

CAS  PubMed  Google Scholar 

Nunes MC, Madhi SA. Review on the immunogenicity and safety of PCV-13 in infants and toddlers. Expert Rev Vacc. 2011;10(7):951–80.

CAS  Google Scholar 

Bonner K, Welch E, Elder K, Cohn J. Impact of pneumococcal conjugate vaccine administration in pediatric older age groups in low and middle-income countries: a systematic review. PLoS ONE. 2015;10(9): e0135270.

PubMed  PubMed Central  Google Scholar 

Althouse BM, Hammitt LL, Grant L, Wagner BG, Reid R, Larzelere-Hinton F, et al. Identifying transmission routes of Streptococcus pneumoniae and sources of acquisitions in high transmission communities. Epidemiol Infect. 2017;145(13):2750–8.

CAS  PubMed  PubMed Central  Google Scholar 

Weaver J, Hu T, Podmore B, Barnett R, Obermüller D, Galetzka W, et al. Incidence of pneumococcal disease in children in Germany, 2014–2019: a retrospective cohort study. BMC Pediatr. 2024;24(1):755.

PubMed  PubMed Central  Google Scholar 

Bertran M, D’Aeth JC, Abdullahi F, Eletu S, Andrews NJ, Ramsay ME, et al. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study. Lancet Infect Dis. 2024;24(5):546–56.

CAS  PubMed  Google Scholar 

Levy C, Cohen R. Pneumococcal conjugate vaccine schedule: 3+ 1, 2+ 1, or 1+ 1? Lancet Child Adolesc Health. 2024;8(11):774–5.

PubMed  Google Scholar 

Lu C-Y, Chiang C-S, Chiu C-H, Wang E-T, Chen Y-Y, Yao S-M, et al. Successful control of Streptococcus pneumoniae 19A replacement with a catch-up primary vaccination program in Taiwan. Clin Infect Dis. 2019;69(9):1581–7.

PubMed  Google Scholar 

van Zandvoort K, Checchi F, Diggle E, Eggo RM, Gadroen K, Mulholland K, et al. Pneumococcal conjugate vaccine use during humanitarian crises. Vaccine. 2019;37(45):6787–92.

PubMed